SurVaxM vaccine study for lung cancer prevention
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether the SurVaxM vaccine can help prevent lung cancer in people who are at high risk because of their smoking history. It is designed for current or former smokers with a significant smoking history.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are a current or former smoker with at least a 20 pack-year smoking history (for example, smoking 1 pack daily for 20 years, or 2 packs daily for 10 years).
- You have a lung cancer risk score above a certain threshold as calculated by a standard health tool.
- You are not taking any other cancer treatments or strong immune-suppressing medications.
- You do not have a history of autoimmune disease or an organ transplant.
- If you have had another cancer, it must have been treated and considered low risk for coming back.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a centralized support program helps people get regular lung cancer screening. If you are at risk for lung cancer and have had a screening CT scan at one of the participating health centers, this study may help improve care.
This study looks at genetic changes in people with suspected or high-risk lung cancer. It aims to use those results to guide more personalized treatment decisions.
This trial tests a combination of two treatments—CIMAvax-EGF (a cancer vaccine) and a KRAS G12C inhibitor (a targeted drug)—for advanced lung cancer with a specific genetic mutation. The goal is to see if adding the vaccine helps the standard KRAS inhibitor work better.
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
This trial tests a vaccine made from a lung-cancer target (MUC1) to help your immune system recognize and fight the cancer. It is designed to measure immune response and safety, and it may help some people develop a stronger anti-cancer immune reaction.
This trial uses a mobile unit to screen people at high risk for lung cancer. It aims to catch the disease early, when it's easier to treat.
Hear when a new Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.